GlobeNewswire by notified

Composition of the Nomination Committee of Orion Corporation

Share

ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
26 APRIL 2024 at 11.15 EEST          


Composition of the Nomination Committee of Orion Corporation

The Board of Directors of Orion Corporation has appointed the following persons to the Nomination Committee of the company:

  • Annika Ekman
  • Petteri Karttunen
  • Minna Maasilta
  • Veli-Matti Mattila
  • Hilpi Rautelin
  • Seppo Salonen

Hilpi Rautelin was appointed as Chair of the Committee.  

The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.

The essentials of the charter of the Nomination Committee and a description of the appointment process of its members are provided at https://www.orion.fi/en/investors/corporate-governance/board-of-directors/nomination-committee/charter-of-the-nomination-committee/ , a page in the Corporate Governance section of the Orion Group website.

Orion Corporation

Liisa Hurme
President and CEO
Olli Huotari
SVP, Corporate Functions


Contact person:
Olli Huotari, SVP, Corporate Functions, Secretary to the Board of Directors of Orion Corporation

tel. +358 10 426 3054

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®6.5.2024 14:30:00 CEST | Press release

OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials.” Ampligen is currently being evaluated as

Investeringsforeningen IA Invest, Afdeling Thygesen Global Stock Selection – Endeligt resultat af tegning6.5.2024 14:23:30 CEST | pressemeddelelse

Investeringsforeningen IA Invest havde indledende tegningsperiode i afdeling Thygesen Global Stock Selection (ISIN: DK0062842134) fra den 22. april til og med den 3. maj 2024. Efter opgørelse af tegningsresultatet for afdeling Thygesen Global Stock Selection er det vurderingen, at afdelingen ikke har opnået en tilstrækkelig stor formue til at blive lanceret og optaget til handel på Nasdaq Copenhagen. Der vil som følge heraf ikke blive udstedt andele i afdeling Thygesen Global Stock Selection. Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00. Med venlig hilsen Niels Erik Eberhard Direktør

Investeringsforeningen IA Invest, Afdeling Furesø Globale Kvalitetsaktier – Endeligt resultat af tegning6.5.2024 14:20:15 CEST | pressemeddelelse

Investeringsforeningen IA Invest havde indledende tegningsperiode i følgende afdeling fra den 22. april til og med den 3. maj 2024. Endeligt resultat af tegningen fremgår nedenfor: AfdelingISINTegningskursAntal investorerAntal cirkulerende andeleFormue kr.Furesø Globale KvalitetsaktierDK0062842217100,2033425.234 42.608.447 De nye andele vil blive optaget til handel på Nasdaq Copenhagen med første handelsdag den 14. maj 2024. For yderligere information henvises der til henholdsvis foreningens og afdelingens hjemmeside www.iainvest.dk og www.furesoekapital.dk. Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00. Med venlig hilsen Niels Erik Eberhard Direktør

Exodus Movement, Inc. Announces Uplist to NYSE American Exchange6.5.2024 14:15:00 CEST | Press release

OMAHA, Neb., May 06, 2024 (GLOBE NEWSWIRE) -- Exodus Movement, Inc. (OTCQX: EXOD) (“Exodus” or the “Company”), the leading self-custodial cryptocurrency software platform, today announced that its common stock has been approved for listing on the NYSE American stock exchange. The Company’s Class A common stock, par value $0.000001 (the “Common Stock”), will begin trading on the NYSE American under its current symbol, “EXOD,” at the open of trading on May 9, 2024. The Common Stock will continue to trade on the OTCQX until the close of market on May 8, 2024. Current stockholders of the Company do not need to take any action prior to the Company’s expected listing on the NYSE American. “Uplisting to the NYSE American marks a significant milestone in our journey. Trading on the NYSE American will allow Exodus to create greater long-term value for our stockholders by increasing our presence within the investor community and, in turn, increase liquidity,” said JP Richardson, CEO and co-found

Wolters Kluwer unveils AI center; Provides direct access to its AI-driven solutions, insights and expertise6.5.2024 14:01:56 CEST | Press release

PRESS RELEASE Wolters Kluwer unveils AI center; Provides direct access to its AI-driven solutions, insights and expertise Alphen aan den Rijn – May 6, 2024 – Wolters Kluwer, a global leader in professional information, software solutions, and services, today unveiled its dedicated AI center. The launch marks the company's ongoing commitment to combining deep domain knowledge with cutting-edge technology such as artificial intelligence (AI), which Wolters Kluwer has been incorporating into its products for the last 10 years. The AI center centralizes the company’s latest AI-insights, research, and AI-driven information solutions in one accessible location, catering to professionals across critical sectors such as health, financial services, legal, ESG, risk, regulatory, and compliance. The site launch includes a recently published fireside chat featuring Wolters Kluwer CEO and Chair of the Executive Board, Nancy McKinstry, on the explosion of AI in the professional sector. Nancy McKinst

HiddenA line styled icon from Orion Icon Library.Eye